Group 1 - The company announced that independent director Peng Long is under investigation for serious violations of discipline and law by the Central Commission for Discipline Inspection and the Supervisory Commission of Linfen City [1] - Peng Long currently serves as the independent director of the company's fourth board, chairman of the board's strategic committee, member of the board's nomination committee, and member of the board's audit committee [1] - The company stated that this matter will not have a significant impact on its production and operational activities [1] Group 2 - The company will continue to monitor the progress of the event and will strictly adhere to information disclosure obligations as required [1]

Core Points - The company announced the first vesting results of the 2024 restricted stock incentive plan, with a total of 418,656 shares vested [1][10] - The shares for this vesting were sourced from the company's repurchase of its A-share common stock from the secondary market [9] Summary of Relevant Sections Decision-Making Process and Disclosure - On April 28, 2024, the company's board and supervisory board approved the draft of the 2024 restricted stock incentive plan and related proposals [2][3] - The plan was publicly disclosed on April 29, 2024, on the Shanghai Stock Exchange website [2] Vesting Details - The total number of shares granted was 1,046,640, with 418,656 shares vested, representing 40% of the granted shares [7] - The vesting included 180 individuals, with core technical personnel and other key employees being the main recipients [9] Stock Source and Structure Changes - The vested shares were sourced from the company's repurchased A-share common stock, meaning there was no change in the total share capital of the company [9] - The controlling shareholder's stake remained unchanged before and after the vesting [9] Verification and Registration - The company received a verification report from an accounting firm confirming the subscription funds for the vested shares, totaling approximately RMB 9.54 million [9][10] - The registration of the vested shares was completed on June 26, 2025, as confirmed by the China Securities Depository and Clearing Corporation [10]

证券代码：688513 证券简称：苑东生物 公告编号：2025-044 成都苑东生物制药股份有限公司 第一个归属期归属结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任公司上海分公司有关业务规则的规定，成都苑东生物制药股份有限公司（以下 简称"公司"）于 2025 年 6 月 27 日收到中国证券登记结算有限责任公司上海分公 司出具的《过户登记确认书》，完成了公司 2024 年限制性股票激励计划（以下简 称"本次激励计划"）首次授予第一个归属期归属的股份登记工作。现将有关情况 公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 （一）2024 年 4 月 28 日，公司召开的第三届董事会第十八次会议，审议通 过了《关于公司<2024 年限制性股票激励计划（草案）>及其摘要的议案》《关于 公司<2024 年限制性股票激励计划实施考核管理办法>的议案》及《关于提请股 东大会授权董事会办理公司 2024 年限制性股票激励计划有 ...

Group 1 - The core viewpoint of the news is that Yuandong Biopharmaceutical is accelerating its strategic transformation by increasing its stake in Shanghai Chaoyang, which specializes in innovative drug development [1][2] - Yuandong Biopharmaceutical's subsidiary plans to acquire approximately 19.32% of Shanghai Chaoyang's shares, raising its indirect ownership from 11.36% to 30.68%, thus gaining significant influence over the company [1] - The acquisition aligns with Yuandong's strategic development plan and is expected to enhance its capabilities in innovative drug research and development [1][2] Group 2 - Shanghai Chaoyang, established in 2021, focuses on innovative drug research in oncology and autoimmune diseases, utilizing advanced technologies such as protein homeostasis and computer-aided drug design [2] - The company has filed 11 invention patent applications and holds 2 authorized patents, with multiple research pipelines targeting various diseases [2] - Experts believe that the increased stake will allow Yuandong to participate more deeply in Shanghai Chaoyang's R&D processes, enhancing its competitive position in the innovative drug sector [2][3] Group 3 - The innovative drug sector is experiencing rapid growth due to advancements in biotechnology and increasing global demand for effective treatments for major diseases [3] - Governments worldwide are implementing policies to support innovative drug development, providing financial backing to enhance research efforts [3] - The integration of emerging technologies like artificial intelligence and big data is expected to improve the efficiency and success rates of innovative drug development [3]

Core Viewpoint - The report highlights the commitment of Yuan Dong Bio to sustainable development through a robust ESG (Environmental, Social, and Governance) framework, emphasizing innovation, compliance, and social responsibility in the pharmaceutical industry [1][2][3]. Group 1: Company Overview - Yuan Dong Bio is dedicated to patient-centered healthcare, focusing on innovation and quality in drug development, with a significant portion of revenue allocated to R&D, exceeding 20% [2][3]. - The company has established a comprehensive governance structure, including a board of directors and various committees to ensure effective decision-making and compliance with regulations [4][5]. Group 2: ESG Commitment - The company integrates ESG principles into its core strategy, aiming for a harmonious balance between environmental sustainability, social responsibility, and corporate governance [1][5]. - Yuan Dong Bio has implemented a three-tier ESG governance structure, comprising the board, an ESG management committee, and an execution team, to oversee and enhance its sustainability initiatives [5]. Group 3: Innovation and Development - The company has a strong focus on innovation, with over 80 ongoing projects, including 18.3% dedicated to new drug development, and has achieved significant milestones in clinical trials [3][5]. - Yuan Dong Bio has successfully launched multiple high-end pharmaceutical products, including 8 domestic first generic products and 14 active pharmaceutical ingredients that meet international standards [3][4]. Group 4: Social Responsibility - The company actively engages in community support initiatives, including healthcare assistance and educational programs, reflecting its commitment to social responsibility and public health [2][5]. - Yuan Dong Bio emphasizes employee welfare and development, recognizing its workforce as a vital asset, and has implemented various programs to support employee growth and well-being [2][5].

Group 1 - After the transaction, Yuandong Bio will indirectly hold a 30.6818% stake in Shanghai Chaoyang, making it a significant influence on the company [1] - The transaction is classified as a related party transaction due to the familial connections between the stakeholders involved [1] - Shanghai Chaoyang focuses on innovative drug development in oncology and autoimmune diseases, utilizing advanced technologies such as protein homeostasis and computer-aided drug design [1][2] Group 2 - Shanghai Chaoyang has a pipeline that includes projects HP001 and HP002, as well as candidates CY-002 and CY-007, and is developing a DAC platform for targeted therapies [2] - The R&D team is led by Dr. Zhao Liwen, who has extensive experience in drug development and has successfully brought multiple drugs into clinical trials [2] - Yuandong Bio views the acquisition of Shanghai Chaoyang's stake as a strategic move to accelerate its innovation transformation [3][4]

经全体与会独立董事审议：公司本次受让参股公司上海超阳药业有限公司部 分股权暨关联交易的事项符合公司战略发展规划，有利于加快推进公司创新转型 战略的实施步伐，具备合理性和必要性。本次交易定价依据各方友好协商，定价 公平、合理，不会损害公司及股东特别是中小股东的利益。我们同意本次受让上 海超阳股权事项，并同意将该议案提请董事会审议。 表决结果：3 票同意、0 票反对、0 票弃权。 独立董事：彭龙、程增江、方芳 2025 年 6 月 26 日 成都苑东生物制药股份有限公司 第四届独立董事专门会议第二次会议决议 成都苑东生物制药股份有限公司（以下称"公司"）第四届独立董事专门会议 第二次会议通知于 2025 年 6 月 24 日以电话通知、电子邮件等形式临时向全体独 立董事发出，会议于 2025 年 6 月 26 日以通讯表决方式召开。本次会议应出席独 立董事 3 名，实际出席独立董事 3 名。本次会议由独立董事彭龙先生召集并主持， 会议的召集、召开及表决程序符合《上市公司独立董事管理办法》等法律法规、 规范性文件和《成都苑东生物制药股份有限公司章程》的规定，会议形成的决议 合法有效。 一、审议通过《关于受让参股公司 ...

证券代码：688513 证券简称：苑东生物 公告编号：2025-043 一、关联交易概述 1 交易标的名称：上海超阳药业有限公司（以下简称"上海超阳"） 交易概述：成都苑东生物制药股份有限公司（以下简称"公司"、"苑东生物"） 全资子公司苑东生物投资管理（上海）有限公司（以下简称"上海投资公 司"）作为投资主体拟受让上海超阳原股东吴汉超、北京齐力佳科技有限公 司（以下简称"齐力佳"）持有的部分股权，其中，拟以 810 万元人民币受让 吴汉超所持有的上海超阳 7.9545%的股权，对应上海超阳注册资本 700 万元； 拟以 1,158 万元人民币受让齐力佳所持有的上海超阳 11.3636%的股权，对 应上海超阳注册资本 1,000 万元；资金来源均为自有资金。 本次交易完成后，公司间接持有上海超阳的股权比例将由 11.3636%增加至 30.6818%，上海超阳将成为公司施加重大影响的参股公司。 本次交易构成关联交易，未构成重大资产重组，本次交易实施不存在重大 法律障碍。 本次交易为公司董事会决策权限范围，无需提交公司股东大会审议。 风险提示：上海超阳是一家致力于创新药研发的生物科技公司，创新药具 有投入大、周 ...

表决结果：同意 3 票，反对 0 票，弃权 0 票。同意票占本次监事会有效表决 票数的 100%，全票表决通过。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《关于受让参股公司部分股权暨关联交易的公告》。 一、监事会会议召开情况 成都苑东生物制药股份有限公司（以下简称"公司"）第四届监事会第五次会 议于 2025 年 6 月 26 日在公司会议室以现场形式召开。会议通知已于 2025 年 6 月 24 日以电话通知、电子邮件等方式临时送达全体监事。本次会议应出席监事 3 名，实际出席监事 3 名，本次会议由监事会主席罗雯婕女士主持，公司董事会 秘书等列席会议。本次会议的召集和召开程序符合有关法律、行政法规、部门规 章、规范性文件和《公司章程》的规定，会议决议合法、有效。 二、监事会会议审议情况 经审议，会议以投票表决的方式通过以下议案： （一）审议通过《关于受让参股公司部分股权暨关联交易的议案》 监事会认为：本次交易的审议及决策程序合法、合规，交易定价依据各方友 好协商，定价公平、合理。本次交易资金来源于公司自有资金，不会对公司现金 流及经营业绩产生重大不利影响，符合公司 ...

证券代码：688513 证券简称：苑东生物 公告编号：2025-041 成都苑东生物制药股份有限公司 第四届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 成都苑东生物制药股份有限公司（以下称"公司"）第四届董事会第五次会议 于 2025 年 6 月 26 日以现场和通讯相结合的方式召开。会议通知已于 2025 年 6 月 24 日以专人送达、电话通知、电子邮件等形式临时送达全体董事。本次会议 由董事长王颖女士主持，应出席董事 9 名，实际出席董事 9 名。本次会议的召集、 召开和表决程序符合《中华人民共和国公司法》等相关法规和《成都苑东生物制 药股份有限公司章程》的规定，会议形成的决议合法有效。 二、董事会会议审议情况 经与会董事审议，逐项表决，形成决议如下： （一）审议通过《关于受让参股公司部分股权暨关联交易的议案》 本议案已经独立董事专门会议和董事会战略委员会审议通过。 董事会认为：公司本次受让参股公司上海超阳药业有限公司部分股权暨关联 交易的事项符合公司战略发展规划 ...